In a Kansas City Star guest commentary (6/25/25 page 14A), Jamie Corley, executive director of the nonprofit Prescription ...

Gov. JB Pritzker signed a pair of health care-related bills Tuesday that he said would put more controls on the pricing of ...

Employers, some lawmakers and others have criticized pharmacy benefit managers (PBMs), especially the "big three," for having ...

Kentucky’s independent pharmacies, facing ongoing financial pressure, had hoped for relief from a new law meant to give them ...

PBMs argue that as middlemen between large pharmaceutical companies and consumers, they save patients money. Middlemen contend that critics have cherry-picked cases while “completely ...

PBMs use their new power over market access and price to extract hundreds of billions of dollars from the market through tactics under investigation by regulators and which, according to my ...

PBMs steering patients to their own pharmacies is also threatening the health of independent pharmacies, testified Hugh Chancy, president of the National Community Pharmacists Association.

PBMs counter by arguing that they save payers (and, by extension, patients) money by increasing buyer power in negotiations with pharma companies. The Pharmaceutical Care Management Association argues ...

PBMs act as an intermediary on behalf of plan sponsors (e.g., employers) to negotiate lower drug prices from brand manufacturers and lower prices at the pharmacy.

PBMs typically negotiate concessions below the nominal list prices of prescription drugs. The PCMA is challenging a provision of the rule set to take effect in January that would require them to ...

PBMs also faced questions on group purchasing organizations, or groups that leverage purchasing power to negotiate drug prices. From 2019 to 2021, the big three PBMs established locations overseas.

The PBMs do not reimburse pharmacies for these transactions, meaning the patients' cash payment represents the pharmacies' only revenue, and PBMs' profits increase, the lawsuits say.